Isomorphic Labs, the AI (Artificial Intelligence) drug design company spun out of Google DeepMind, announced a $2.1 billion Series B financing, marking one of the largest private rounds to date for an AI-native pharmaceutical developer. <cite index="2-1,2-3">The London-headquartered company disclosed the round on May 12, 2026, describing itself as an "AI-first drug design and development company."</cite>
Round structure and investors
<cite index="2-5">The financing was led by Thrive Capital, with participation from existing backers Alphabet and GV alongside new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund.</cite> The syndicate combines U.S. growth capital, sovereign vehicles from Singapore and the United Arab Emirates, and the United Kingdom government's dedicated AI fund—an unusually broad geographic base for a private biotech round.
The Series B follows an earlier external raise. <cite index="3-5">Isomorphic brought in $600 million via its first external funding round a year ago and has now followed up with the $2.1 billion Series B.</cite> <cite index="3-4">The London-based AI drug discovery firm was founded by Alphabet in 2021 with a mission to develop a number of AI models that, together, will form its unified drug design engine.</cite>
Technology and pipeline
Proceeds are earmarked for the company's proprietary platform and its in-house therapeutic candidates. <cite index="2-6">The new capital will be used for the continued development and deployment of Isomorphic Labs' AI drug design engine (IsoDDE), accelerating and expanding its pipeline of therapeutic programs towards the clinic.</cite> <cite index="3-8">Isomorphic designs potential drugs with AI models such as AlphaFold 3, a Google DeepMind–partnered model that can predict the structures and interactions of molecules.</cite> <cite index="8-16,8-17">The company is built on software that DeepMind developed, including its Nobel Prize–winning AlphaFold, which predicts protein structures, and is researching treatments for cancer and immune disorders.</cite>
<cite index="2-7">Isomorphic said the funding will also support hiring targets across AI, engineering, drug design, and clinical talent at its global sites.</cite>
Pharma partnerships
The company's commercial validation rests heavily on collaborations with established drugmakers. <cite index="2-17,2-18">Isomorphic Labs maintains a portfolio of strategic partnerships with industry leaders including Novartis, Lilly, and Johnson & Johnson, which the company frames as validation of its AI-first approach and the value it brings to the pharmaceutical industry.</cite>
Leadership commentary
<cite index="2-13,2-14,2-15">Founder and CEO Sir Demis Hassabis called the round "a massive vote of confidence" in the company's AI-first approach, adding that with the approach "fundamentally sound," the focus shifts to scaling the technology and building out the drug design engine.</cite> <cite index="2-11,2-12">Ruth Porat, President and Chief Investment Officer of Alphabet and Google, said Isomorphic has "already made extraordinary progress in harnessing AI to accelerate drug discovery," and that the funding will be used to bring interventions to market with greater speed.</cite>
Context
The round is notable for its size relative to typical biotech Series B financings, which historically rarely exceed several hundred million dollars. It also reflects an investor thesis that AI-driven structural biology—anchored by models such as AlphaFold—has matured from research demonstration into a near-term commercial category. <cite index="2-19,2-20">Isomorphic Labs was founded in 2021 to transform drug discovery with the power of artificial intelligence and is led by CEO Sir Demis Hassabis and President Max Jaderberg.</cite> The company has not disclosed a post-money valuation, the clinical stage of its internal candidates, or a timeline for first human trials of wholly owned programs.